Difficulty: Medium
Average Score: 70%
Practice
Regarding drugs used in Parkinson's disease, which statement is true?
Correct answer
D
Rationale
The correct answer is D) Amantadine has anti-Parkinsonian effects and is administered at a dose of 100mg bd.
Rationale:
Amantadine is an antiviral drug that also exhibits anti-Parkinsonian effects by increasing dopamine release and reducing dopamine reuptake. It is commonly used as an adjunct therapy in Parkinson's disease. The dosing regimen of 100mg twice daily is standard to achieve optimal therapeutic effects while minimizing side effects.
Option A is incorrect because Bromocriptine is not the first-line drug for treating Parkinson's disease in psychotic patients. Dopamine agonists like pramipexole or ropinirole are often preferred.
Option B is incorrect as only about 1-5% of a single dose of Levodopa enters the brain unaltered. The rest is metabolized peripherally, leading to side effects like nausea and dyskinesias.
Option C is incorrect because while Selegiline is a MAO-B inhibitor used in Parkinson's disease, the dietary restrictions for tyramine-rich foods are associated with non-selective MAO inhibitors like phenelzine, not with Selegiline.
In an educational context, understanding the pharmacology of CNS drugs in Parkinson's disease is crucial for healthcare professionals to provide optimal care for patients. Proper knowledge of drug mechanisms, dosing regimens, and potential side effects is essential for safe and effective treatment. This question highlights the importance of accurate drug information in managing Parkinson's disease.
Rationale:
Amantadine is an antiviral drug that also exhibits anti-Parkinsonian effects by increasing dopamine release and reducing dopamine reuptake. It is commonly used as an adjunct therapy in Parkinson's disease. The dosing regimen of 100mg twice daily is standard to achieve optimal therapeutic effects while minimizing side effects.
Option A is incorrect because Bromocriptine is not the first-line drug for treating Parkinson's disease in psychotic patients. Dopamine agonists like pramipexole or ropinirole are often preferred.
Option B is incorrect as only about 1-5% of a single dose of Levodopa enters the brain unaltered. The rest is metabolized peripherally, leading to side effects like nausea and dyskinesias.
Option C is incorrect because while Selegiline is a MAO-B inhibitor used in Parkinson's disease, the dietary restrictions for tyramine-rich foods are associated with non-selective MAO inhibitors like phenelzine, not with Selegiline.
In an educational context, understanding the pharmacology of CNS drugs in Parkinson's disease is crucial for healthcare professionals to provide optimal care for patients. Proper knowledge of drug mechanisms, dosing regimens, and potential side effects is essential for safe and effective treatment. This question highlights the importance of accurate drug information in managing Parkinson's disease.